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Echolucent femoral plaques entail higher risk of
echolucent carotid plaques and a more severe
inflammatory profile in peripheral arterial disease
Giusy Sirico, MD, Gregorio Brevetti, MD, Simona Lanero, MD, Eugenio Laurenzano, MD,
Rossella Luciano, MD, and Massimo Chiariello, MD, Naples, Italy
Objective: Plaque instability is recognized as a multivessel phenomenon related to inflammation. This study examined if
the morphology of femoral plaques was related to that of carotid plaques.
Methods: The echogenicity of femoral and carotid plaques of 102 patients with peripheral artery disease (PAD) was
studied and classified as echolucent or echorich according to the gray-scale median (GSM) value, which was 53.6 for
femoral plaques and 55.2 for carotid plaques. Serum C-reactive protein (CRP) levels and neutrophil count were also
measured.
Results: Echolucent carotid plaques were more frequent in patients with echolucent than in those with echorich femoral
plaques (55.8% vs 32.0%; P< .01). At multivariate analysis, femoral GSM lower than the median was the only significant
predictor of echolucent carotid plaques (odds ratio [OR], 3.87; 95% confidence interval [CI], 1.53-9.83). Patients with
echolucent femoral plaques had higher serum CRP levels (P < .01) and a higher neutrophil count (P  .029) than
patients with echorich femoral plaques. However, univariate analysis showed that neutrophil count (OR, 3.48; 95% CI,
1.23-9.85) but not hs-CRP was associated with echolucent carotid plaques. At multivariate analysis, neutrophil count
exceeding the median remained associated with echolucent carotid plaques (OR, 5.71; 95% CI, 1.37-23.85), whereas the
association between femoral and carotid echolucency was attenuated (OR, 3.75; 95% CI, 0.98-4.43).
Conclusions: In PAD, the presence of echolucent femoral plaques is associated with a greater prevalence of echolucent
carotid plaques, probably as a consequence of a more pronounced inflammatory profile. This confirms and extends the
finding that plaque echolucency is a multivessel phenomenon. Prospective studies are needed to assess whether carotid
screening in PAD patients might contribute to improving clinical decision-making. (J Vasc Surg 2009;49:346-51.)Several recent studies indicate that atherosclerotic
plaque instability may not be confined to a single vascular
bed but may also involve other arterial districts.1 Indeed,
patients with unstable carotid or femoral plaques were
more likely to have unstable plaques in the contralateral
artery.2,3 Complex carotid plaques were also associated
with complex coronary stenoses4 and with acute coronary
syndromes.5,6 Finally, patients with echolucent, probably
unstable carotid plaques, were at increased risk of coronary
events than were patients with echorich carotid plaques.7,8
Inflammation may be a link between carotid and coronary
plaque instability.
Inflammatory cell infiltrates were detected in multiple
coronary plaques of patients with acute coronary syn-
dromes and in carotid plaques of patients with recent
cerebrovascular ischemic events.9-11 Furthermore, the
presence of high-risk plaques is associated with increased
systemic levels of inflammatory markers.5,6,12-14
Although the association between carotid and coronary
plaques has been extensively investigated in its epidemio-
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346logic, pathophysiologic, and clinical aspects, less is known
about the association of unstable femoral plaques with
unstable plaques in other vascular districts. Coronary arter-
ies are not easy targets for noninvasive imaging, but femoral
and carotid arteries can be investigated by B-mode ultra-
sound imaging. In particular, plaque echogenicity has been
found to reliably predict plaque composition. Plaques that
appear echolucent present an inflammatory infiltration11
and are lipid-rich, whereas those with high echogenicity
have more fibrous tissue and greater calcification, which
makes them more stable.15,16
Because patients with peripheral arterial disease (PAD)
often present inflamed, echolucent plaques in their leg
arteries,3,17,18 we hypothesized that (1) echolucent femo-
ral plaques are associated with a greater prevalence of
echolucent plaques in the carotid arteries than are echorich
femoral plaques, and (2) echolucent femoral plaques are
associated with evidence of systemic inflammation.
METHODS
Study subjects and clinical history. We originally
screened 205 consecutive subjects referred to our vascular
laboratory for suspected intermittent claudication. PAD
was diagnosed on the basis of an ankle-brachial index (ABI)
0.90 associated with one or more stenoses 50% in the
arteries supplying the legs.
Clinical history and risk factors were assessed at enroll-
ment. Smokers included current smokers. Hypertension
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or diastolic arterial pressure was 90 mm Hg, or if the
patient used antihypertensive drugs. Hypercholesterolemia
was diagnosed if plasma total cholesterol level was 240
mg/dL, if plasma low-density lipoprotein cholesterol was
130 mg/dL, or if the patient used lipid-lowering drugs
because of a history of hypercholesterolemia. Diabetes mel-
litus was diagnosed if the plasma fasting glucose level was
26mg/dL or if the patient used hypoglycemic agents. All
126 patients gave their informed consent to the protocol,
which was approved by the ethics committee of our insti-
tution.
Assessment of femoral and carotid arteries. B-mode
ultrasound images as well as velocity recordings of femoral
arteries and carotid bifurcations were obtained and ana-
lyzed by a single investigator unaware of the patient’s
clinical status to ensure uniformity of the applied ultrasono-
graphic criteria and blindness. For a more comprehensive
evaluation of the severity of the carotid disease in PAD, we
assessed also a number of patients without carotid plaques
and a number of patients with carotid stenosis50%. In no
case was the analysis of the femoral plaques followed by the
analysis of the carotid plaques of the same patient.
Images were recorded onto super-VHS videotape and
digitized with PixelView, Hi Speed USB 2.0 TV/Capture
box (Prolink Microsystems Corp, Taipei, Taiwan). Plaques
detected in the femoral artery were registered in the 15-mm
section proximal to the bifurcation, in the bifurcation area,
or in the proximal parts of the superficial and profound
femoral arteries. In cases where plaque was present in both
femoral arteries, the plaque with greater echolucency was
used for the analysis. The same criterion was used for
carotid bifurcations.
After duplex scanning, blood was drawn from an ante-
cubital vein using a 19-gauge needle in a Vacutainer system
(BD Diagnostics, Franklin Lakes, NJ). C-reactive protein
(CRP) was measured in the serum using a high-sensitivity
(hs) assay (Dade Behring Diagnostics/Siemens, Deerfield,
Ill). Neutrophil count was measured with the Technicon
H*2 hematology analyzer (Bayer-Sankyo, Tokyo, Japan).
The Image Processing and Analysis in Java (Image J)
software was used for standardization and echogenicity
analysis in the computer-assisted analysis. Plaque echoge-
nicity, assessed by a computer-assisted technique, is as-
sociated with optimal reproducibility.19,20 The gray-
scale median (GSM) of the frequency distribution of grey
values of the pixels within the plaque served as a measure
of echogenicity. Standardization was obtained as previ-
ously reported.21
After standardization, the plaque was outlined and its
overall brightness evaluated by means of GSM grey-scale
range of 0 (black) to 255 (white). The GSM value of the
plaque was adjusted linearly so that the median value of
blood was 0 and that of adventitia was 190. The GSM value
was used to divide plaques in echolucent and echorich. We
previously assessed the intraobserver reproducibility for
carotid plaque echogenicity with satisfactory results ( 
0.83).20 Also the intraobserver reproducibility for femoralplaque echogenicity, assessed in 23 plaques, was satisfactory
(  0.79).
The inclusion criterion for this study was the presence
of femoral and carotid plaques 1.3 mm in thickness,
which is the limit suggested by the Prevention Conference
V22 and used in most studies on plaque echogenicity.12,23
Patients with smaller plaques were not included because
such plaques could not be clearly separated from diffused
thickened intima–media complex. Other exclusion criteria
were (1) absence of femoral plaques; (2) calcified femoral or
carotid plaques with an acoustic shadow, or occlusion of
carotid arteries or femoral arteries in the tract explored for
the analysis, because it was technically impossible to deter-
mine their echogenicity reliably; and (3) revascularization
of femoral or carotid arteries under the assumption that the
revascularized artery was that at higher risk. Also excluded
were patients with critical limb ischemia, unstable angina,
recent (6 months) cerebrovascular accidents or myocar-
dial infarction, and any other inflammatory conditions that
could alter plaque composition and neutrophil count and
CRP levels.
Statistical analyses. The Kolmogorov-Smirnov test
was used to assess the normality of the variable distribution.
GSM value, CRP level, and neutrophil count were non-
normally distributed and thus were expressed as median
(interquartile range) and compared by the Mann-Whitney
U test. Normally distributed continuous variables (age and
ABI) were expressed as mean  SD and compared by the
unpaired t test. Categoric variables were compared by the
2 test. Correlations between variables were evaluated by
Spearman analysis. Multivariate regression analyses were
used to identify the factors independently associated with
echolucent carotid plaques. The analysis was adjusted for
age, sex, diabetes mellitus, active smoking, hypercholester-
olemia, and hypertension. A second multivariate analysis
was adjusted also for hs-CRP serum levels and neutrophil
count.
RESULTS
A total of 102 PAD patients were eligible for this study.
The reasons for the exclusion of 103 patients are listed in
Table I. Table II summarizes the main characteristics of the
study population divided according to the median GSM
Table I. Reasons for the exclusion from the study
Reason No. (%)
No peripheral arterial disease 18 (8.8)
Absence of plaques in femoral common arteries 9 (4.4)
Femoral or carotid plaques 1.3 mm 9 (4.4)
Calcified femoral or carotid plaques 15 (7.3)
Revascularization of femoral or carotid plaques 21 (10.2)
Occlusion of femoral or carotid arteries in the tract
explored 20 (9.7)
Critical limb ischemia 3 (1.5)
Recent (6 months), unstable angina, CVA or MI 8 (3.9)
CVA, cerebrovascular event; MI, myocardial infarction.value of the femoral plaques, which was 53.6 (range, 30.0-
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traditional risk factors, ABI, and cardiovascular treatments
between patients with echolucent plaques (GSM  53.6)
and those with echorich plaques (GSM  53.6).
Carotid plaques were absent in 7 of 52 patients (13.5%)
with echolucent and in 4 of 50 patients (8.0%) with
echorich femoral plaques (P  .374). Similarly, no differ-
ence was noted in the prevalence of carotid artery stenoses
50% between the two groups (19.2% vs 16.0%, respec-
tively). However, echolucent carotid plaques, defined as
those with median GSM 55.2 (range, 30.0-74.7) were
observed in 29 of 52 patients (55.8%) with echolucent
femoral plaques and in only 16 of 50 (32.0%) with echorich
femoral plaques (P  .01). In addition, after the exclusion
of patients without carotid plaque, the 91 remaining pa-
tients with plaques in both arteries showed a strong associ-
ation between echolucent femoral plaques and echolucent
carotid plaques.
As shown in Fig 1, the carotid GSM score was lower in
patients with echolucent femoral plaques than in patients
with echorich femoral plaques, at 45.0 (range, 14.2-63.6)
vs 66.8 (range, 46.2-82.6), respectively (P  .01). The
femoral GSM score was also significantly related to the
carotid GSM score (  0.28, P  .01). Even more
important, multivariate analysis adjusted for age, sex, and
traditional risk factors showed that the femoral GSM value
lower than the median was the only significant predictor of
the presence of echolucent plaques in carotid arteries (odds
ratio [OR], 3.87; 95% confidence interval [CI], 1.53-9.83,
P  .01). The femoral GSM scores were unrelated to the
ABI.
Patients with echolucent femoral plaques had higher
hs-CRP levels and neutrophil counts than patients with
Table II. Characteristics of the study population
Variable
Femoral GSM score
P
Median
(echolucent
plaque)
Median
(echorich
plaques)
Patients, No. 52 50
Age, mean  SD, y 66.5  9.6 65.2  10.2 .503
Males, No. (%) 41 (78.8) 42 (84.0) .408
Hypercholesterolemia,
No. (%) 35 (66.7) 39 (78.0) .163
Diabetes mellitus, No. (%) 26 (50.0) 21 (42.0) .472
Hypertension, No. (%) 46 (88.5) 40 (80.0) .240
Active smoking, No. (%) 22 (42.3) 21 (42.0) .975
ABI, mean  SD 0.68  0.14 0.66  0.23 .674
Stenosis 50%, No. (%)
Femoral 12 (23.1) 9 (18.0) .526
Carotid 10 (19.2) 8 (16.0) .563
Treatment, No. (%)
Antiplatelets 46 (88.5) 42 (84.0) .513
ACE inhibitors 40 (76.9) 32 (64.0) .152
Statins 27 (51.9) 33 (66.0) .149
ABI, Ankle-brachial index; ACE, angiotensin-converting enzyme; GSM,
gray-scale median.echorich femoral plaques, being 3.6 mg/L (range, 2.5-5.8mg/L) vs 2.0 mg/L (range, 1.4-3.5 mg/L; P  .01), and
4.5 mg/L (range, 3.9-5.4 mg/L) 103/	L vs 4.1 mg/L
(range, 2.9-4.9 mg/L) 103/	L (P .005), respectively
(Fig 2). At univariate analysis, however, echolucent carotid
plaques were associated with increased neutrophil count
(OR, 3.48; 95% CI, 1.23 to 9.85; P  .019), but not with
increased levels of hs-CRP (OR, 1.04; 95% CI, 0.77-1.42;
P  .792).
To assess whether inflammatory markers modify the
capacity of femoral GSM in predicting the presence of
echolucent carotid plaque, we included the neutrophil
count in multivariate analyses. The results show that a
neutrophil count exceeding the median remained associ-
ated with echolucent carotid plaques (OR, 5.71; 95% CI,
1.37-23.85; P  .017). In this model, the association
between femoral and carotid echolucency only approached
statistical significance (OR, 3.75; 95% CI, 0.98-14.43; P
.05; Table III).
DISCUSSION
To our knowledge, this is the first study to show that
PAD patients with an echolucent plaque in the femoral
artery have a threefold higher risk of having an echolucent
plaque in the carotid arteries than do PAD patients with
echorich femoral plaques. This increased risk was inde-
pendent of age, sex, cardiovascular classic risk factors, and
PAD severity measured as ABI. Compared with echorich
plaques, those that appear echolucent on B-mode ultra-
sound imaging have inflammatory infiltration11 and an
increased lipid content that makes them vulnerable and
thus more prone to rupture.24,25 Indeed, echolucent
Fig 1. Carotid gray-scale median (GSM) in patients with echolu-
cent and echorich femoral plaque. Results are shown as median
(lines), interquartile ranges (boxes), and 10th and 90th percentile
(bars).plaques are associated with an increased cerebrovascular
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Volume 49, Number 2 Sirico et al 349risk.26,27 Previous studies2,3,5 and this study report that an
echolucent and presumably unstable plaque in an individ-
ual may occur simultaneously in different parts of the
arterial tree. This hypothesis may explain why both echolu-
cent carotid and femoral plaques are associated with an
increased risk of future ischemic events in other territories
compared with echorich plaques.7,8,18,28,29
An important mechanism underlying plaque vulnera-
bility is inflammation.30 In fact, inflammatory cell infiltrates
were detected in multiple coronary plaques of patients who
died from acute coronary syndromes and in carotid plaques
of patients with recent cerebrovascular ischemic events.9-11
Furthermore in the same subjects, high systemic levels of
inflammatory markers were associated with unstable plaques
in multiple vascular districts.5,31,32
Echolucent unstable femoral plaques have been previ-
ously described in PAD.18,28,29 We now report that these
plaques are associated with increased levels of systemic
markers of inflammation.
In our study, serum hs-CRP concentrations and neu-
trophil count were both higher in patients with echolucent
Fig 2. Left, High-sensitivity C reactive protein (hs-CR
and echorich femoral plaque. Results are shown as me
percentile (bars).
Table III. Predictors of hypoechoic carotid plaques at mu
Predictor
Model 1
OR (95% CI)
Femoral GSM median 3.87 (1.53-9.83)
Age 1.02 (0.97-1.08)
Sex 1.35 (0.43-4.27)
Active smoking 0.92 (0.35-2.43)
Hypercholesterolemia 1.98 (0.68-5.79)
Diabetes 1.35 (0.54-3.35)
Hypertension 0.67 (1.80-2.51)
Neutrophil count median . . .
CI, Confidence interval; GSM, gray-scale median; OR, odds ratio.femoral plaques than in patients with echorich plaques.However, univariate analysis showed that neutrophil count,
but not CRP, was associated with echolucent carotid
plaques. These findings are difficult to explain, but they are
in agreement with previous reports that carotid plaque
echolucency, although being strongly associated with neu-
trophil or leukocyte count, is not related to systemic levels
of CRP.12,33 Notably, when the neutrophil count exceed-
ing the median was added to the other covariates, the
association between femoral and carotid plaque echolu-
cency was no longer significant. This finding, probably due
to the more pronounced inflammatory profile in patients
with echolucent femoral plaques, highlights the role of
inflammation in echolucent, unstable plaques.
The present study has some limitations. First, we used
the median of GSM score as an arbitrary cutoff point to
distinguish echolucent from echorich plaques; however,
to our knowledge, no GSM cutoff has been established to
identify echolucent plaques. Thus far, various cutoffs have
been used,34-36 among them median GSM.15,34 Second,
because this study is cross sectional, we cannot evaluate
whether a causal relationship exists between inflammatory
d (Right) neutrophil count in patients with echolucent
(lines), interquartile ranges (boxes), and 10th and 90th
riate analyses
Model 2
P OR (95% CI) P
.004 3.75 (0.97-14.43) .055
.341 1.01 (0.93-1.08) .842
.610 0.31 (0.05-2.04) .222
.871 0.28 (0.06-1.25) .095
.211 0.71 (0.15-3.40) .666
.519 2.91 (0.67-12.62) .153
.553 9.87 (0.60-16.40) .111
. . . 5.71 (1.37-23.85) .017P) an
dianltivamarkers and a lower femoral plaque echogenicity.
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Many patients affected by claudication with unstable
plaques in the femoral arteries also have unstable plaques in
the carotid arteries. Therefore, this study confirms and
extends previous reports that plaque echolucency, which
probably reflects plaque instability, may be a multivessel
phenomenon that could have important clinical implica-
tions. Indeed, current guidelines underestimate the need
for carotid screening in PAD. The American College of
Cardiology/American Heart Association guidelines37 do
not provide any recommendation, and the TransAtlantic
InterSociety Consensus for the Management of Peripheral
Arterial Disease (TASC II)38 recommends evaluation of the
carotid circulation only in PAD patients with previous
transient ischemic attacks or stroke. However, the defini-
tion of screening inmedicine is “the examination of a group
of usually asymptomatic individuals to detect those with a
high probability of having a given disease, typically by
means of an inexpensive test.”39
Given the close association between echolucent carotid
plaques and cardiovascular events,7,8,31 our data suggest
that PAD patients with echolucent plaques in the femoral
arteries, even in the absence of previous cerebrovascular
events, should undergo B-mode ultrasound carotid screen-
ing to improve the selection for carotid endarterectomy or
to select patients for specific anti-inflammatory therapies.
However, larger, prospective studies are needed to assess
the cost effectiveness of carotid screening in PAD patients
with echolucent femoral plaques.
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